摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-Oxazolyl)benzenemethanamine | 1211529-03-1

中文名称
——
中文别名
——
英文名称
2-(2-Oxazolyl)benzenemethanamine
英文别名
[2-(1,3-oxazol-2-yl)phenyl]methanamine
2-(2-Oxazolyl)benzenemethanamine化学式
CAS
1211529-03-1
化学式
C10H10N2O
mdl
——
分子量
174.2
InChiKey
FXIIJLSVCDPHPZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    332.6±44.0 °C(Predicted)
  • 密度:
    1.155±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    52
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
    申请人:Lead Discovery Center GmbH
    公开号:EP2634190A1
    公开(公告)日:2013-09-04
    The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.
    本发明涉及吡唑并[1,5-a][1,3,5]三嗪衍生物和/或其药用可接受盐,以及这些衍生物作为药用活性剂的用途,特别是用于预防和/或治疗传染病,包括机会性疾病、免疫疾病、自身免疫疾病、心血管疾病、细胞增殖性疾病、炎症、勃起功能障碍和中风,以及含有至少一种所述吡唑并[1,5-a][1,3,5]三嗪衍生物和/或其药用可接受盐的药物组合物。此外,本发明涉及将所述吡唑并[1,5-a][1,3,5]三嗪衍生物用作蛋白激酶的抑制剂
  • OXAZOLE TYROSINE KINASE INHIBITORS
    申请人:Sareum Limited
    公开号:US20130102592A1
    公开(公告)日:2013-04-25
    The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar 1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted en by one or more substituents R 1 ; Ar 2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R 2 ; and R 1 and R 2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.
    本发明提供了一种化合物,其为公式(1)的酰胺或其盐、溶剂合物、N-氧化物或互变异构体;其中:a为0或1;b为0或1:前提是a和b的和为0或1;T为O或NH;Ar1为含有最多4个来自O、N和S的杂原子的单环或双环5-至10-成员芳基或杂芳基基团,并且可以被一个或多个取代基R1取代;Ar2为含有最多4个来自O、N和S的杂原子的单环或双环5-至10-成员芳基或杂芳基基团,并且可以被一个或多个取代基R2取代;R1和R2如权利要求所定义。该化合物是激酶抑制剂,特别是FLT3、FLT4和Aurora激酶抑制剂
  • PYRAZOLO-TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS
    申请人:Lead Discovery Center GmbH
    公开号:EP2820020B1
    公开(公告)日:2016-04-06
  • US20140275041A1
    申请人:——
    公开号:US20140275041A1
    公开(公告)日:2014-09-18
  • US8378095B2
    申请人:——
    公开号:US8378095B2
    公开(公告)日:2013-02-19
查看更多